ClinicalTrials.gg
WithdrawnNCT02661087Updated Aug 7, 2020

Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility

An interventional study of Hysteroscopic resection with bipolar energy and Hysteroscopic resection with monopolar energy in Symptomatic Submucosal Myoma, sponsored by Brugmann University Hospital. Withdrawn at 2 sites in 2 countries. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2020-08-07.

Sponsored by Brugmann University Hospital · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Principal investigator departure
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Study summary

Since the development in the last few years of the bipolar energy in the surgery by hysteroscopy, the hysteroscopic treatment of the submucosal uterine myoma can be performed by use of either monopolar or bipolar current.

It seems that the use of the bipolar energy decreases the rate of adhesions but prospective data on the adhesion rate and fertility after the use of bipolar energy during the surgery are poor, and there is currently no recommendation as to the choice of technique to use. The main purpose of this study is to compare the rate of uterine adhesions six weeks after the surgical hysteroscopic treatment of uterine submucosal myoma, by using monopolar or bipolar energy. The pregnancy and spontaneous miscarriage rate will also be evaluated.

Read the detailed description

Uterine fibroids are detected in many cases of excessive bleeding or consultation for primary or secondary infertility. When they are of the submucosal type, they require a surgical treatment by hysteroscopy. The hysteroscopic resection of submucosal fibroids described by Neuwirth and Amin in 1976 allowed to reduce the morbidity, the length of hospital stay and the cost of the therapeutic treatment, with a satisfactory rate of functional successes.

The surgical hysteroscopic treatment of symptomatic submucosal myoma was performed initially by a monopolar endoscopic resection. This required a resection using glycine as a distension medium, essential for the conduction of monopolar current.

Complications proper to the monopolar resection have been described and are now well known. The first specific complication is the TURP syndrome, linked to the reabsorption of the glycine byproducts of the distensium medium. It can cause hyponatremia and lead to a cerebral edema. This complication can be prevented by limiting the duration of the intervention to 45 minutes and constantly monitoring the input-output balance.

The second specific complication is related to the diffusion of heat that can damage to surrounding healthy tissue and increase the risk of uterine adhesions. These adhesions are the source of menstrual disorders like hypomenorrhea or amenorrhea, infertility or a recurrent miscarriages.

For over 20 years, several approaches have been proposed to reduce the occurrence of postoperative adhesions. However, their results are either not convincing, either in need of confirmation.

Since several years, the use of the bipolar energy for hysteroscopic resection has been developped.The advantage of this technique is to avoid glycine as distension medium and use saline instead, hereby significantly reducing the risk of hyponatremia. It especially gives a smaller heat diffusion, hereby limiting the damage to the healthy tissues nearby.

Although hysteroscopic bipolar resection of submucosal fibroids is now a routine technique, there are to this date no studies in the literature comparing the use of monopolar and bipolar energy in the hysteroscopic myomectomy.

The main objective of this study is to compare the rate of adhesions after resection of uterine myomas, with the use of bipolar versus monopolar current. The secondary objective is to evaluate the impact on subsequent fertility through the number of pregnancies and miscarriages.

02

Conditions studied

  • Symptomatic Submucosal Myoma

Browse trials for

Keywords

  • submucosal myoma
  • hysteroscopic resection
  • bipolar energy
  • monopolar energy
03

In context

Myoma

61 studies on the registry are indexed under Myoma; 10 are open to participants now.

Browse Myoma studies →

Lead sponsor

Brugmann University Hospital is the lead sponsor of 117 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic (menorrhagia or primary/secondary infertility) with pregnancy wishes
  • One submucosal myoma, type 0 to Type II, accessible to a hysteroscopic surgery

Exclusion criteria

Exclusion Criteria:

  • Several submucosal myomas
  • Pregnant woman
  • Patient under anticoagulating treatment (anti-vitamin K-type)
  • Patient with a malignant endometrial pathology
  • Patient having one or more endo-uterine synechiae
  • Myoma larger than 5 cm
  • Uterine malformation
  • Active infection, not healed
  • Refusal to participate in the Protocol
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Bipolar energy

    Hysteroscopic resection of symptomatic sub mucosal myomas with the use of bipolar energy

    Procedure: Hysteroscopic resection with bipolar energy

  • Active comparator
    Monopolar energy

    Hysteroscopic resection of symptomatic sub mucosal myomas with the use of monopolar energy

    Procedure: Hysteroscopic resection with monopolar energy

Interventions

  • ProcedureHysteroscopic resection with bipolar energy

    Hysteroscopic resection with bipolar energy

  • ProcedureHysteroscopic resection with monopolar energy

    Hysteroscopic resection with monopolar energy

06

What researchers measure

Primary outcomes

  1. uterine adhesions rate

    The main goal of this study is to compare the rate of uterine adhesions six weeks after the hysteroscopic surgical treatment of sub mucosal uterine myomas, in a group where bipolar energy is used versus a group where monopolar energy is used during the surgery. Outcome measured at the diagnostic hysteroscopic visit, 6 weeks after surgery.

    Time frame: 6 weeks after surgery

Secondary outcomes

  1. Pregnancy rate

    Number of evolutive pregnancies - phone contact 18 months after surgery

    Time frame: 18 months after surgery

  2. Spontaneous abortion rate

    Number of spontaneous abortions - phone contact 18 months after surgery

    Time frame: 18 months after surgery

  3. Surgery duration

    Duration of the surgical intervention

    Time frame: From the entry to the exit of the hysteroscope from the body. Ambulatory surgery, max 1 day

  4. Per-surgery complications rate

    Complications rate during the surgery duration

    Time frame: From the entry to the exit of the hysteroscope from the body. Ambulatory surgery, max 1 day

  5. Post-surgery complications rate

    Post-surgery complications rate, measured at the diagnostic hysteroscopic visit performed 6 weeks after surgery.

    Time frame: 6 weeks after surgery

07

Study locations

2 sites
  • CHU Brugmann
    Brussels, 1020, Belgium
  • CHU Bicêtre, Kremlin Bicêtre
    Le Kremlin Bicêtre, 94270, France
08

References and documents

Publications

  • Neuwirth RS, Amin HK. Excision of submucus fibroids with hysteroscopic control. Am J Obstet Gynecol. 1976 Sep 1;126(1):95-9. doi: 10.1016/0002-9378(76)90471-3. PubMed 961753 ↗
  • Valle RF, Sciarra JJ. Intrauterine adhesions: hysteroscopic diagnosis, classification, treatment, and reproductive outcome. Am J Obstet Gynecol. 1988 Jun;158(6 Pt 1):1459-70. doi: 10.1016/0002-9378(88)90382-1. PubMed 3381869 ↗
  • Jewelewicz R, Khalaf S, Neuwirth RS, Vande Wiele RL. Obstetric complications after treatment of intrauterine synechiae (Asherman's syndrome). Obstet Gynecol. 1976 Jun;47(6):701-5. PubMed 934560 ↗
  • Taskin O, Sadik S, Onoglu A, Gokdeniz R, Erturan E, Burak F, Wheeler JM. Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery. J Am Assoc Gynecol Laparosc. 2000 Aug;7(3):351-4. doi: 10.1016/s1074-3804(05)60478-1. PubMed 10924629 ↗
  • Acunzo G, Guida M, Pellicano M, Tommaselli GA, Di Spiezio Sardo A, Bifulco G, Cirillo D, Taylor A, Nappi C. Effectiveness of auto-cross-linked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic adhesiolysis: a prospective, randomized, controlled study. Hum Reprod. 2003 Sep;18(9):1918-21. doi: 10.1093/humrep/deg368. PubMed 12923149 ↗
  • Guida M, Acunzo G, Di Spiezio Sardo A, Bifulco G, Piccoli R, Pellicano M, Cerrota G, Cirillo D, Nappi C. Effectiveness of auto-crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery: a prospective, randomized, controlled study. Hum Reprod. 2004 Jun;19(6):1461-4. doi: 10.1093/humrep/deh238. Epub 2004 Apr 22. PubMed 15105384 ↗
  • Vilos GA, Abu-Rafea B. New developments in ambulatory hysteroscopic surgery. Best Pract Res Clin Obstet Gynaecol. 2005 Aug;19(5):727-42. doi: 10.1016/j.bpobgyn.2005.06.012. Epub 2005 Aug 26. PubMed 16126460 ↗
  • Touboul C, Fernandez H, Deffieux X, Berry R, Frydman R, Gervaise A. Uterine synechiae after bipolar hysteroscopic resection of submucosal myomas in patients with infertility. Fertil Steril. 2009 Nov;92(5):1690-3. doi: 10.1016/j.fertnstert.2008.08.108. Epub 2008 Oct 19. PubMed 18937941 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Dec 2019, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2016
First posted
Jan 22, 2016
StartActual
Mar 14, 2017
Primary completionActual
Dec 3, 2019
CompletionActual
Dec 3, 2019
Last update
Aug 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02661087
Responsible party
Andre Nazac (Head of Clinic, Brugmann University Hospital) — Principal investigator
First posted
Jan 22, 2016
Start date
Mar 14, 2017
Primary completion
Dec 3, 2019
Completion
Dec 3, 2019
Last update
Aug 7, 2020

Study contacts

André Nazac, MD
principal investigator · CHU Brugmann

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion